DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0143956A1 Cady Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0143956A1 Cady Et Al US 2013.0143956A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0143956A1 Cady et al. (43) Pub. Date: Jun. 6, 2013 (54) LONG-ACTING INJECTABLE MOXIDECTIN (22) Filed: Nov.30, 2012 FORMULATIONS AND NOVEL MOXDECTIN CRYSTAL FORMS Related U.S. Application Data (71) Applicants: Susan Mancini Cady, Yardley, PA (US); (60) Provisional application No. 61/566,336, filed on Dec. Baoqing Ma, Kendall Park, NJ (US); 2, 2011. Robert Clark Chapman, Downingtown, Publication Classification PA (US); Chunhua Yang, Edison, NJ (US); Uday Jain, Plainsboro, NJ (US) (51) Int. Cl. A6IK3I/365 (2006.01) (72) Inventors: Susan Mancini Cady, Yardley, PA (US); (52) U.S. Cl. Baoqing Ma, Kendall Park, NJ (US); CPC .................................... A61 K3I/365 (2013.01) Robert Clark Chapman, Downingtown, USPC ............................ 514/450; 549/264; 264/145 PA (US); Chunhua Yang, Edison, NJ (US); Uday Jain, Plainsboro, NJ (US) (57) ABSTRACT This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric (73) Assignee: Merial Limited, Duluth, GA (US) implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and pre (21) Appl. No.: 13/690,185 Venting of endo- and ectoparasite infections in animals. Patent Application Publication Jun. 6, 2013 Sheet 1 of 33 US 2013/0143956 A1 FIG. I. Six: Restivati Masaaaaaaaaaaaaaaaaaaaaaaaaaaa estivate 83 3 R33 Patent Application Publication Jun. 6, 2013 Sheet 2 of 33 US 2013/0143956 A1 FIG 2A Conventional DSC of Moxidectin lot SO9060: ... -- ; : f; : : ^ ‘s 1119°C f ---. f - “r-. f a. -: ; Agree 18649°Cs f 2) skirt" ----. - 23.46°C & i 114.31°CY --.-1N 1.64J/g A. e 173.48°C -3. --- - d : 6.91349 f i. : I i . i : 206.06°C -2.8-i 25 75 125 175 225 Temperature (°C) Patent Application Publication Jun. 6, 2013 Sheet 3 of 33 US 2013/0143956 A1 FIG. 2B Conventional DSC of Moxidectin lot S080701 3.3. ; ; : : - f ”ssaaa. : is irs is 34.6°C f - --- 1,561Jg ; Y- --- f \s s 11-78°C f a. s ---...-- - \ Ny ----r-.2.167J/g f f o A2. --- er 108.13°C :117.10°C ---. ---...--- / w Y/ ---...s. - 2 ses: Y red i s d I s r t r r y r T •r 25 75 25 75 225 Temperature (C) Patent Application Publication Jun. 6, 2013 Sheet 4 of 33 US 2013/0143956 A1 FIG. 3 PRXD of MOxidectin lot S090601 Theta-2Theta deg) Patent Application Publication Jun. 6, 2013 Sheet 5 of 33 US 2013/0143956 A1 FIG. 4 3 - f : : 193OC shai, Ya-Ye : i e f a -3- f **s- f v-Yas :s ^s. **. 104.15°C 3 d : ------- - 3267/g ... 196.18C vis----. : 7,591.J.g / “r.ris-1-X--- : 108.53°C : i d ; i 200.7°C 2 25: 75 T is r 175 225 T Temperature (°C) Patent Application Publication Jun. 6, 2013 Sheet 6 of 33 US 2013/0143956 A1 FIG. 5 ... -- 198OC 2ss s f sc.-si-. 10.7°C / 3. ---. k- 993 186.33°C ? e “--...-3, 19827C A Yale- 114.82°C *::s;12,30J/g Y *:::: * 3. 4.953.3/g173.18°C S-i- f s f t 202.7°C 25 75 125 175 225 Temperature (°C) Patent Application Publication Jun. 6, 2013 Sheet 7 of 33 US 2013/0143956 A1 FIG. 6 'srx & i x.--- f ---. 110.98°C 88.43°C f ------, 1,895J/g Sik.**x. 20353°C- Y - / 15.39°C-- *x.se: *-3--- 12.68Jig : 73.55°C 7.051Jig 25 75 25 75 225 Temperature (C) Patent Application Publication Jun. 6, 2013 Sheet 8 of 33 US 2013/0143956 A1 FIG. 7 & a. so - Yale 3) s f Y-a- tec S s a \ Ast 2 Yae -------; **- y A š. e 162.54c ---.S. Y s e 28.3%ig r- - : s C- y i i -. -) Non-reversible Heat Flow ------ - ? Y,\ \ i| - . & ”O.S is92 I ss., - 2 2 S f--- ...if12.15°C) I'--------...-a-ka-i. t A2 i w 17.18Jig s: : 40.5°C 36.2°C W . - 0.8 Non-reversible Heat Flow (W/g) Y 22.84°C s: - - r-ir-i -r r-, -:0 A. 90 40 19C 240 Temperature (C) FIG. 8 Moxidectin after 190 °C bath c -------------------------------------------------------------------------------------------------------------------------------------- S. 2. s Theta-2Theta (deg) Patent Application Publication Jun. 6, 2013 Sheet 9 of 33 US 2013/0143956 A1 FIG. 9 Moxidectin ot O906O1 035: 30: 025 020: 0. s 005 Wave numbers (cm) Patent Application Publication Jun. 6, 2013 Sheet 10 of 33 US 2013/0143956 A1 FIG 10 Moxidectirot O906O1 i as iv r . v-Y ---------- is v W.A.A.A.R.' ot Ososol, he at 185°C Raman Shift (cm) Patent Application Publication Jun. 6, 2013 Sheet 11 of 33 US 2013/0143956 A1 FIG. 1 1 (1/2) Patent Application Publication Jun. 6, 2013 Sheet 12 of 33 US 2013/0143956 A1 FIG. I. 1 (2/2) Patent Application Publication Jun. 6, 2013 Sheet 13 of 33 US 2013/0143956 A1 FIG. 12 FIG. 13 PXRD of Air-dried Moxidectin/MeCH crystals Theta-2Theta (deg) Patent Application Publication Jun. 6, 2013 Sheet 14 of 33 US 2013/0143956 A1 Temperature (C) FIG. I.5 88. 21158°C 43.8 s DSC of air-dried moxidectin MeCH crystals 213.66°C -3.3--- -T- -T --- -- t 25 75 25 175 225 Temperature (C) Patent Application Publication Jun. 6, 2013 Sheet 15 of 33 US 2013/0143956 A1 FG 7 *** Patent Application Publication Jun. 6, 2013 Sheet 16 of 33 US 2013/0143956 A1 s: - - - - - - - - - - - - - - - - -:-:- Delta Y -1187.4% \ TGA of air-dried moxidectin/EtOH crystals . Temperature (C) Patent Application Publication Jun. 6, 2013 Sheet 17 of 33 US 2013/0143956 A1 FIG. 19 DSC of air-dried moxidectin/EtOH crystals y f * 8-s-Xs. ---------- ---. * -----------. &*- : :: : 3.2 - g : 2.8- r y 25 75 125 175 FIG. 20 88: - Se: DSC of vacuum-dried moxidectin/EtOH crystals Y . : s - ---. : --- : : ---. -------------- : ---. - : --- ^. -3.3 :: -r- 2.8 .i y 25 75 125 75 225 Patent Application Publication Jun. 6, 2013 Sheet 18 of 33 US 2013/0143956 A1 Patent Application Publication Jun. 6, 2013 Sheet 19 of 33 US 2013/0143956 A1 Patent Application Publication Jun. 6, 2013 Sheet 20 of 33 US 2013/0143956 A1 FIG. 24 Patent Application Publication Jun. 6, 2013 Sheet 21 of 33 US 2013/0143956 A1 FIG. 25 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- C - - - - . PXRD of air-dried moxidectin/PA crystals 3 - - - . : Patent Application Publication Jun. 6, 2013 Sheet 22 of 33 US 2013/0143956 A1 TGA of air-dried moxidectin/PA crystals Delta Yc-14.8.76% FIG. 28 27.9°C 358.3.g 125 75 225 275 Patent Application Publication Jun. 6, 2013 Sheet 23 of 33 US 2013/0143956 A1 FIG. 29 4 : 278.75°C DSC of vacuum-dried moxidectin/PA 8. 116.68°C 2. “r-.............. 11779°C(1) 17.70°C “r........ 264.76°C 44, J/g 3 -i------------~~~~~~~~~~~ 25 75 125 175 225 275 Patent Application Publication Jun. 6, 2013 Sheet 24 of 33 US 2013/0143956 A1 FIG. 31 3. PXRD of air-dried moxidectin/ n-Butanol crystals 38) - . s s s s s s TGA of air-dried noxidectin? n-Butanol crystals Sri - - - - - - - - - - - - - - -... Delta Y = 14.938% . Patent Application Publication Jun. 6, 2013 Sheet 25 of 33 US 2013/0143956 A1 3.3 : s DSC of air-dried moxidectin f n-Butano crystals 3.3 - 21.92* 45, 40.J.g f t47.32°C 34.83°C 21469C --- is 25 DSC of vacuum-dried moxidectin? n-Butanol crystals at 60 C - - 8.4 N. ris ? s: y ^ - s - “r----...-r --- --- 8. --------- -8.8 25- is s is 25 Patent Application Publication Jun. 6, 2013 Sheet 26 of 33 US 2013/0143956 A1 FIG 35 PXRD of noxidectin/n-Butano S3 . crystals after vacuum drying at 65 °C se is l's 2i. S 3, 3.3 : : DSC of vacuum-dried moxidectin/n-Butanol crystals at RT : : 65°C 29.57°C 32.84 - : -3.3 ---. 24.78Jig -** am 9 - ---...-- -- . : Ys...--^ ---.” : i y : i -- : : i : i : : 5 : 88.00°C : : 232.93C : 33.-- r : 25 75 25 175 225 Patent Application Publication Jun. 6, 2013 Sheet 27 of 33 US 2013/0143956 A1 FIG. 37 : - : Patent Application Publication Jun. 6, 2013 Sheet 28 of 33 US 2013/0143956 A1 FIG. 39 SS . ionioi--oxo TGA of air-dried noxidectin/MCH crystals : FIG. 40 DSC of air-dried moxidectin/MCH crystals 3.5- / v. ---------. * i “r-ra-re--... - -1.8- 25 75 125 75 223 Patent Application Publication Jun. 6, 2013 Sheet 29 of 33 US 2013/0143956 A1 (Y s & s: t - ; w w s v Patent Application Publication Jun. 6, 2013 Sheet 30 of 33 US 2013/0143956 A1 FIG 42 Patent Application Publication Jun. 6, 2013 Sheet 31 of 33 US 2013/0143956 A1 ***********… (~~~~)-g(0- Patent Application Publication Jun. 6, 2013 Sheet 32 of 33 US 2013/0143956 A1 FIG. 44 in Vitro Release of Formulation (75:25 DEG, 0.4 iv) -O-438-148 O 5 10 15 20 25 3O 35 Elapsed Time, days FIG. 45 -Are Ot OO588-17 O 5 1 O 15 20 25 30 35 ELAPSED TIME (days) Patent Application Publication Jun. 6, 2013 Sheet 33 of 33 US 2013/0143956 A1 1,000 0.100 ovo. -0-Average Moxidectin Plasma levels 0.010 to- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -: O 50 1 OO 150 20 250 US 2013/014395.6 A1 Jun. 6, 2013 LONG-ACTING INUECTABLE MOXDECTIN “tune' the polymer/beneficial agent formulation to enable it FORMULATIONS AND NOVEL MOXDECTIN to be stable and to release at the desired rate.
Load more

Recommended publications
  • Bulletin Leading the Fight Against Heartworm Disease
    BULLETIN LEADING THE FIGHT AGAINST HEARTWORM DISEASE SEPTEMBER HEARTWORM 2017 Q&A VOLUME 44 No. 3 Heartworm History: In What Year Was Heartworm First INSIDE THIS ISSUE Treated? Page 4 From the President Page 8 Research Update Abstracts from the Literature Page 14 Heartworm Hotline: Role of Heat Treatment in Diagnostics Page 19 NEW! Best Practices: Minimizing Heartworm Transmission in Relocated Dogs uestions from members, prac- published in the 1998 AHS Symposium 1 titioners, technicians, and the Proceedings. Dr. Roncalli wrote, “The Page 21 Qgeneral public are often submit- first trial to assess the efficacy of a Welcome Our New AHS ted to the American Heartworm Society microfilaricide (natrium antimonyl tar- Student Liaisons (AHS) via our website. Two of our AHS trate) was conducted some 70 years Board members, Dr. John W.McCall and ago (1927) in Japan by S. Itagaki and R. Page 25 Dr. Tom Nelson, provided the resources Makino.2 Fuadin (stibophen), a trivalent In the News: Surgeons to answer this question: In What Year antimony compound, was tested, intra- Remove a Heartworm from Was Heartworm First Treated? venously, as a microfilaricide by Popescu the Femoral Artery of a Cat The first efforts to treat canine heart- in 1933 in Romania and by W.H. Wright worm disease date back to the 1920s. Dr. and P.C. Underwood in 1934 in the USA. Page 26 Nelson referenced a review article by Dr. In 1949, I.C. Mark evaluated its use Quarterly Update Raffaele Roncalli, “Tracing the History of intraperitoneally.” What’s New From AHS? Heartworms: A 400 Year Perspective,” Continues on page 7 American Heartworm Society / PO Box 8266, Wilmington, DE 19803-8266 Become an American Heartworm Society www.heartwormsociety.org / [email protected] fan on Facebook! Follow us on Twitter! OUR GENEROUS SPONSORS PLATINUM LEVEL PO Box 8266 Wilmington, DE 19803-8266 [email protected] www.heartwormsociety.org Mission Statement The mission of the American Heartworm Society is to lead the vet- erinary profession and the public in the understanding of heartworm disease.
    [Show full text]
  • Computational Studies of Drug Repurposing Targeting P-Glycoprotein Mediated Multidrug-Resistance Phenotypes in Agents of Neglect
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.12.147926; this version posted June 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Computational studies of drug repurposing targeting P- glycoprotein mediated multidrug-resistance phenotypes in agents of neglected tropical diseases Nivedita Jaishankar 1, Sangeetha Muthamilselvan 2, Ashok Palaniappan 1,2* 1 Department of Biotechnology, Sri Venkateswara College of Engineering, Post Bag No. 1, Pennalur, Sriperumbudur Tk 602117. India 2 Department of Bioinformatics, School of Chemical and BioTechnology, SASTRA Deemed University, Thanjavur 613401. India * Corresponding author: [email protected] ABSTRACT Mammalian ABCB1 P-glycoprotein is an ATP- dependent efflux pump with broad substrate specificity associated with cellular drug resistance. Homologous to this role in mammalian biology, the P-glycoprotein of agents of neglected tropical diseases (NTDs) mediates the emergence of multidrug- resistance phenotypes. The clinical and socioeconomic implications of NTDs are exacerbated by the lack of research interest among Big Pharma for treating such conditions. This work aims to characterise P-gp homologues in certain agents of key NTDs, namely (1) Protozoa: Leishmania major, Trypanosoma cruzi; (2) Helminths: Onchocerca volvulus, Schistosoma mansoni. PSI-BLAST searches against the genome of each of these organisms confirmed the presence of P-gp homologues. Each homologue was aligned against five P- gp sequences of known structure, to identify the most suitable template based on sequence homology, phylogenetic nearest neighbor, and query coverage.
    [Show full text]
  • Veterinary Guide to Resistance & Parasites
    Veterinary Guide to Resistance & Parasites How to make the Get Rotation Right deworming strategy part of your equine health wellness protocol. ||||||||||||||||||||||||||||||||||||||||| GET ROTATION RIGHT Resistant parasites – veterinary involvement is needed now. Deworming has come a long way in the past 50 years – from products that were nearly toxic and required complicated tubing to the easy-to-administer dewormers we know now. As more horse owners recognize the value of regular deworming, past troublemakers such as large strongyles have become much less of a threat. Still, deworming is nothing to take lightly. As internal parasites become more resistant, your expertise is needed Horseowners unknowingly more than ever to make sure deworming programs remain efficient contribute to resistance. and effective. Only with veterinary involvement will we control parasite • Rotating brand names, not populations, combat resistance and get rotation right. chemical classes – general confusion about when and RESISTANCE IS REAL: MULTIPLE DRUGS, MULTIPLE PARASITES. how to use different classes • No new drug class since avermectins in 1981. of dewormers. • Benzimidazole resistance in cyathostomes.1-3 • Lack of knowledge about • Pyrantel resistance in cyathostomes and ascarids.4-8,11 resistance issues. • Ivermectin and moxidectin resistance among ascarids.8,9,11 • Deworming many horses more • Early warning signs of macrocyclic-lactone-resistant cyathostomes.10 frequently than necessary. • Health-related issues caused by parasites: • Misunderstanding about the ~ Ascarids (roundworms) unique properties of larvicidal Verminous pneumonia: cough, nasal discharge, low-grade fever treatments and how to maximize Unthriftiness – rough hair coat their efficacy. Intestinal obstruction/colic • Underdosing their horses. Intestinal perforation leading to peracute death Decreased performance and reduced weight gain ~ Cyathostomes (small strongyles) Most common in young and old horses, but can afflict any horse.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Table of Contents Introduction
    TABLE OF CONTENTS INTRODUCTION............................................................................................................. 2 DEFINITIONS .................................................................................................................. 2 ADVERSE EVENT REPORTING FOR ANIM AL DRUGS ....................................... 4 CANINE HEARTW ORM DISEASE.............................................................................. 7 M ACROCYCLIC LACTONES ...................................................................................... 8 PROHEART 6 PRODUCT INFORM ATION ............................................................... 8 REGULATORY HISTORY OF PROHEART 6 ......................................................... 10 ADE REPORTS FOR PROHEART 6 AND OTHER HEARTW ORM PREVENTIVES .............................................................................................................. 11 PROHEART 6 ADES ..................................................................................................... 16 TRENDS IN PROHEART 6 ADE REPORTING ....................................................... 19 CLINICAL M ANIFESTATIONS ................................................................................. 22 ANAPHYLAXIS/ANAPHYLACTOID REACTIONS ................................................................ 22 CONVULSIONS ................................................................................................................ 24 LIVER SIGNS..................................................................................................................
    [Show full text]
  • 210867Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210867Orig1s000 OTHER REVIEW(S) Clinical Inspection Summary (CIS) NDA 210867 (Moxidectin) Clinical Inspection Summary Date May 31, 2018 From John Lee, M.D., Medical Officer Janice Pohlman, M.D., M.P.H., Team Leader Kassa Ayalew, M.D., M.P.H., Branch Chief Good Clinical Practice Assessment Branch (GCPAB) Division of Clinical Compliance Evaluation (DCCE) Office of Scientific Investigations (OSI) To Kristine Park, Ph.D., Regulatory Project Manager Hiwot Hiruwy, M.D., Ph.D., Medical Officer Dmitri Iarikov, M.D., Ph.D., Clinical Team Leader Sumati Nambiar, M.D., M.P.H., Director Division of Anti-Infective Products (DAIP) Application NDA 210867 Applicant Medicines Development for Global Health (MDGH) Drug Moxidectin (trade name pending) NME Yes Review Status Priority Proposed Indication Treatment of ochocerciasis due to Onchocerca volvulus Consultation Date December 15, 2017 CIS Goal Date June 1, 2018 Action Goal Date June 13, 2018 PDUFA Due Date June 13, 2018 I. OVERALL ASSESSMENT OF FINDINGS Studies 3110A1-200-GH and 3110A1-3000-AF/ONCBL60801 were audited at good clinical practice (GCP) inspections of a clinical investigator (CI) and a contract research organization (CRO). For both inspections, the establishment inspection report (EIR) has not been received from the field office and the inspection outcome shown is based on preliminary communication with the field investigator. Both inspections revealed significant GCP deficiencies, typically (apparently) deficiencies in recordkeeping (Form FDA 483 issued at CI inspection, not issued at CRO inspection). Evidence of serious deficiencies indicative of unreliable study data was not observed and study conduct otherwise appeared GCP-compliant.
    [Show full text]
  • Efficacy of Albendazole and Moxidectin and Resistance To
    Veterinary Parasitology 189 (2012) 387–389 Contents lists available at SciVerse ScienceDirect Veterinary Parasitology jo urnal homepage: www.elsevier.com/locate/vetpar Short communication Efficacy of albendazole and moxidectin and resistance to ivermectin against Libyostrongylus douglassii and Libyostrongylus dentatus in ostriches a a b Lara Pereira de Souza , Rosane Teixeira Lelis , Igor Rio Apa Granja , a a,∗ Renato Augusto DaMatta , Clóvis de Paula Santos a Laboratório de Biologia Celular e Tecidual, Centro de Biociências e Biotecnologia, Universidade Estadual do Norte Fluminense, 28013-602 Campos dos Goytacazes, RJ, Brazil b Rioapavestruzes, 28013-600 Guarani, MG, Brazil a r t i c l e i n f o a b s t r a c t Article history: Anthelmintic resistance has emerged globally as a problem amongst nematode of livestock Received 17 February 2012 and has been particularly well documented in equine and small ruminants. There are no Received in revised form 18 April 2012 studies regarding the efficacy of anthelmintics against the hematophagous nematodes in Accepted 20 April 2012 ostriches, Libyostrongylus dentatus; and just a few on L. douglassii. Here the efficacy of alben- dazole, ivermectin and moxidectin were evaluated against these two species in an ostrich Keywords: farm in Minas Gerais state, Brazil. The feces were collected on the day of treatment and Libyostrongylus douglassii after 13 days of an oral dose of albendazole (6 mg/kg), or an injected dose (0.2 mg/kg) of Libyostrongylus dentatus ivermectin or moxidectin. The fecal egg count reduction test and coprocultures were per- Anthelmintic resistance Ostrich formed to determine possible resistance against the drugs used.
    [Show full text]
  • Parasiticides: Fenbendazole, Ivermectin, Moxidectin Livestock
    Parasiticides: Fenbendazole, Ivermectin, Moxidectin Livestock 1 Identification of Petitioned Substance* 2 3 Chemical Names: 48 Ivermectin: Heart Guard, Sklice, Stomectol, 4 Moxidectin:(1'R,2R,4Z,4'S,5S,6S,8'R,10'E,13'R,14'E 49 Ivomec, Mectizan, Ivexterm, Scabo 6 5 ,16'E,20'R,21'R,24'S)-21',24'-Dihydroxy-4 50 Thiabendazole: Mintezol, Tresaderm, Arbotect 6 (methoxyimino)-5,11',13',22'-tetramethyl-6-[(2E)- 51 Albendazole: Albenza 7 4-methyl-2-penten-2-yl]-3,4,5,6-tetrahydro-2'H- 52 Levamisole: Ergamisol 8 spiro[pyran-2,6'-[3,7,1 9]trioxatetracyclo 53 Morantel tartrate: Rumatel 9 [15.6.1.14,8.020,24] pentacosa[10,14,16,22] tetraen]- 54 Pyrantel: Banminth, Antiminth, Cobantril 10 2'-one; (2aE, 4E,5’R,6R,6’S,8E,11R,13S,- 55 Doramectin: Dectomax 11 15S,17aR,20R,20aR,20bS)-6’-[(E)-1,2-Dimethyl-1- 56 Eprinomectin: Ivomec, Longrange 12 butenyl]-5’,6,6’,7,10,11,14,15,17a,20,20a,20b- 57 Piperazine: Wazine, Pig Wormer 13 dodecahydro-20,20b-dihydroxy-5’6,8,19-tetra- 58 14 methylspiro[11,15-methano-2H,13H,17H- CAS Numbers: 113507-06-5; 15 furo[4,3,2-pq][2,6]benzodioxacylooctadecin-13,2’- Moxidectin: 16 [2H]pyrano]-4’,17(3’H)-dione,4’-(E)-(O- Fenbendazole: 43210-67-9; 70288-86-7 17 methyloxime) Ivermectin: 59 Thiabendazole: 148-79-8 18 Fenbendazole: methyl N-(6-phenylsulfanyl-1H- 60 Albendazole: 54965-21-8 19 benzimidazol-2-yl) carbamate 61 Levamisole: 14769-72-4 20 Ivermectin: 22,23-dihydroavermectin B1a +22,23- 21 dihydroavermectin B1b 62 Morantel tartrate: 26155-31-7 63 Pyrantel: 22204-24-6 22 Thiabendazole: 4-(1H-1,3-benzodiazol-2-yl)-1,3- 23 thiazole
    [Show full text]
  • Tutorial Article a Review of the Use of Moxidectin in Horses J
    EVE 08-054 Schumacher 17/9/08 09:34 Page 2 546 EQUINE VETERINARY EDUCATION / AE / october 2008 Tutorial Article A review of the use of moxidectin in horses J. SCHUMACHER* AND J. TAINTOR Department of Clinical Sciences, J.T. Vaughan Teaching Hospital, College of Veterinary Medicine, Auburn University, Alabama, 36849-5522, USA. Keywords: horse; moxidectin; ivermectin; cyathostomins; ascarids; ectoparasites; resistance Summary which are produced naturally from soil-dwelling Streptomyces microorganisms, are divided into 2 classes of anti-parasitic Moxidectin has broad-spectrum anti-nematodal and drugs, the avermectins and the milbemycins. The first anti-arthropodal activities in the horse but is not macrocyclic lactone introduced to the equine market was the effective against tapeworms or flukes. Moxidectin and avermectin, ivermectin, which was introduced in 1981. That ivermectin have the same efficacy against internal, adult drug revolutionised control of endoparasites and ectoparasites parasites of horses. Moxidectin, however, is highly in many different species because of its relative safety and effective in eliminating encysted and hypobiotic larval efficacy against most economically important parasitic stages of cyathostomins, whereas ivermectin is not. diseases. Since the introduction of ivermectin, other Treatment of horses with moxidectin results in an egg- macrocyclic lactones have been introduced, including reappearance period (ERP) of 15–24 weeks. Because of albamectin, eprinomectin, doramectin, selamectin, moxidectin its long ERP, moxidectin is labelled to be used at and milbemycin A3/A4. Ivermectin, albamectin and 12 week intervals. Moxidectin may provide protection moxidectin are marketed for use in horses. against infection by ingested cyathostomin larvae for 2–3 weeks after it is administered.
    [Show full text]
  • Sheet1 Page 1 a Abamectin Acetazolamide Sodium Adenosine-5-Monophosphate Aklomide Albendazole Alfaxalone Aloe Vera Alphadolone A
    Sheet1 A Abamectin Acetazolamide sodium Adenosine-5-monophosphate Aklomide Albendazole Alfaxalone Aloe vera Alphadolone Acetate Alpha-galactosidase Altrenogest Amikacin and its salts Aminopentamide Aminopyridine Amitraz Amoxicillin Amphomycin Amphotericin B Ampicillin Amprolium Anethole Apramycin Asiaticoside Atipamezole Avoparcin Azaperone B Bambermycin Bemegride Benazepril Benzathine cloxacillin Benzoyl Peroxide Benzydamine Bephenium Bephenium Hydroxynaphthoate Betamethasone Boldenone undecylenate Boswellin Bromelain Bromhexine 2-Bromo-2-nitropan-1, 3 diol Bunamidine Buquinolate Butamisole Butonate Butorphanol Page 1 Sheet1 C Calcium glucoheptonate (calcium glucoheptogluconate) Calcium levulinate Cambendazole Caprylic/Capric Acid Monoesters Carbadox Carbomycin Carfentanil Carnidazole Carnitine Carprofen Cefadroxil Ceftiofur sodium Centella asiatica Cephaloridine Cephapirin Chlorine dioxide Chlormadinone acetate Chlorophene Chlorothiazide Chlorpromazine HCl Choline Salicylate Chondroitin sulfate Clazuril Clenbuterol Clindamycin Clomipramine Clopidol Cloprostenol Clotrimazole Cloxacillin Colistin sulfate Copper calcium edetate Copper glycinate Coumaphos Cromolyn sodium Crystalline Hydroxycobalamin Cyclizine Cyclosporin A Cyprenorphine HCl Cythioate D Decoquinate Demeclocycline (Demethylchlortetracycline) Page 2 Sheet1 Deslorelin Desoxycorticosterone Pivalate Detomidine Diaveridine Dichlorvos Diclazuril Dicloxacillin Didecyl dimethyl ammonium chloride Diethanolamine Diethylcarbamazine Dihydrochlorothiazide Diidohydroxyquin Dimethylglycine
    [Show full text]
  • Pest Management Strategic Plan for Beef Cattle in Tennessee and Kentucky
    Pest Management Strategic Plan for Beef Cattle in Tennessee and Kentucky Summary of Workshops held in January 2005 Princeton, KY and Nashville, TN Prepared by J. Patrick Parkman, IPM Coordinator University of Tennessee Institute of Agriculture Contact: J. Patrick Parkman (865) 974-7138 [email protected] Sponsored by the Southern Region Integrated Pest Management Center, USDA Cooperative State Research, Education and Extension Service Executive Summary With a combined total of 2,238,000 beef cows, Kentucky and Tennessee are the top two beef cattle production states east of the Mississippi. Cash receipts for cattle and calves sales in 2004 totaled $620,650,000 for Kentucky (15% of all receipts) and $514,338,000 for Tennessee (20% of all receipts). In Tennessee, cattle and calves is the leading agricultural commodity. The significance of this industry underscores the importance of reviewing the status of beef cattle pest management in these states and making recommendations for improvement. This document presents the conclusions of two one-day meetings involving producers and state Extension personnel. The meetings were held in response to regulatory actions such as the Food Quality Protection Act which may affect availability of pest management products; to the emergence of new technologies; and to ongoing and new threats to the industry such as pesticide resistance and increased pest pressure. The document includes an overview of production practices, pest incidence and importance, and current pest management practices. Arthropods are far and away the most important pest of cattle in these states, therefore, these pests are given the most emphasis. The priorities developed by meeting participants and published here should serve as a guideline to researchers, Extension personnel, regulators and industry leaders when addressing pest management issues facing beef cattle producers in Kentucky and Tennessee.
    [Show full text]
  • Alpaca and Llama Parasite Treatment
    Alpaca and Llama Parasite Treatment Albendazole (Valbazen) 10mg/kg Do not recommend in pregnancy or for young crias! Much better for killing tapeworms than Fenbendazole. Give orally - 6cc/100 pounds of body weight. Give one dose once per day for three days in a row (max). May need to repeat in two weeks depending on parasite load. May also have an ovacidal effect – meaning that it kills eggs and thus prevents pasture contamination – therefore it is good for isolation pens. Doramectin (Dectomax) 1cc/50 pounds of body weight every 8 weeks. Or give 1cc/70 pounds of body weight every 6 weeks. Give SubQ. (Recommend 20 gauge needle) Primarily for Meningeal Worm prevention. May kill some strongyles. Probably ineffective against most Nematodirus and Trichuris. Ivermectin (Ivomec) 1cc/70 pounds of body weight for Meningeal Worm prevention. Note that efficacy lasts for no more than 4 weeks max! Excellent for mange treatment: Dose at 1cc/50 pounds for mange – 3 days in row, and then repeat one dose in one week. Do not give mange treatment to pregnant females within first 60 days of pregnancy! Give SubQ. (Recommend 20 gauge needle) Probably ineffective in llamas and alpacas for Trichuris, Nematodirus, Moniezia, some strongyles, and liver flukes. You can purchase Ivomec Plus to kill liver flukes. Fenbendazole (Panacur or Safeguard) 20mg/kg or 1cc/10 pounds of body weight Give orally three days in row for Nematodirus. Give orally 5 days in a row and repeat in 2 weeks for Trichuris and Moneizia (tapeworms). This is a very safe drug, even for very young crias and newly pregnant females! Levamisole 8mg/kg Oral drug is safer than the injectible version.
    [Show full text]